Agenus Inc Cash Flow Conversion Efficiency
Agenus Inc cash flow conversion efficiency. Based on the latest financial reports, Agenus Inc (AGEN) has a cash flow conversion efficiency ratio of 0.152x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.20 Million) by net assets ($-205.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Agenus Inc (1999–2025)
Cash flow conversion efficiency of Agenus Inc from 1999 to 2025. This chart illustrates how Agenus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Agenus Inc stock price for real-time trading data and today's change.
Agenus Inc Cash Flow Conversion Ratio Explained
Agenus Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Agenus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Agenus Inc ranked by their cash flow conversion efficiency. Also see Agenus Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NHN KCP Corp
KQ:060250
|
0.513x |
|
Suzhou Fushilai Pharmaceutical Co. Ltd.
SHE:301258
|
N/A |
|
Eaton Vance Senior Floating Rate Closed Fund
NYSE:EFR
|
0.098x |
|
Eikon Therapeutics, Inc. Common Stock
NASDAQ:EIKN
|
-0.139x |
|
Chengdu Rainbow Appliance Gr
SHE:003023
|
-0.053x |
|
Isabella Bank Corporation
NASDAQ:ISBA
|
0.031x |
|
M1 Kliniken AG
XETRA:M12
|
0.129x |
|
MOZAYYX Acquisition Corp.
NYSE:MZYX
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Agenus Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Agenus Inc from 1999 to 2025. Review AGEN cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-277.86 Million | $-158.31 Million | 0.570x | +10.28% |
| 2024-12-31 | $-306.42 Million | $-158.31 Million | 0.517x | -65.81% |
| 2023-12-31 | $-148.38 Million | $-224.20 Million | 1.511x | -52.70% |
| 2022-12-31 | $-54.90 Million | $-175.37 Million | 3.194x | +1408.48% |
| 2021-12-31 | $47.91 Million | $10.14 Million | 0.212x | -67.80% |
| 2020-12-31 | $-211.50 Million | $-139.10 Million | 0.658x | +714.39% |
| 2019-12-31 | $-231.34 Million | $-18.68 Million | 0.081x | -89.25% |
| 2018-12-31 | $-174.55 Million | $-131.09 Million | 0.751x | -39.57% |
| 2017-12-31 | $-75.82 Million | $-94.23 Million | 1.243x | -39.19% |
| 2016-12-31 | $-39.13 Million | $-79.96 Million | 2.044x | +406.40% |
| 2015-12-31 | $70.73 Million | $-47.18 Million | -0.667x | +59.85% |
| 2014-12-31 | $23.02 Million | $-38.23 Million | -1.661x | -138.11% |
| 2013-12-31 | $-4.48 Million | $-19.53 Million | 4.359x | +5274.33% |
| 2012-12-31 | $-12.02 Million | $1.01 Million | -0.084x | -110.80% |
| 2011-12-31 | $-20.83 Million | $-16.25 Million | 0.780x | -22.26% |
| 2010-12-31 | $-14.71 Million | $-14.76 Million | 1.003x | -29.59% |
| 2009-12-31 | $-16.98 Million | $-24.19 Million | 1.425x | +17.91% |
| 2008-12-31 | $-23.92 Million | $-28.91 Million | 1.209x | +113.12% |
| 2007-12-31 | $-47.06 Million | $-26.69 Million | 0.567x | -78.05% |
| 2006-12-31 | $-17.39 Million | $-44.94 Million | 2.584x | +224.26% |
| 2005-12-31 | $31.90 Million | $-66.33 Million | -2.079x | -267.49% |
| 2004-12-31 | $106.44 Million | $-60.22 Million | -0.566x | -16.33% |
| 2003-12-31 | $105.25 Million | $-51.19 Million | -0.486x | +25.60% |
| 2002-12-31 | $77.76 Million | $-50.83 Million | -0.654x | -34.79% |
| 2001-12-31 | $75.92 Million | $-36.83 Million | -0.485x | -274.02% |
| 2000-12-31 | $116.70 Million | $-15.13 Million | -0.130x | +50.34% |
| 1999-12-31 | $51.70 Million | $-13.50 Million | -0.261x | -- |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvan… Read more